Last reviewed: June 1, 2026
2013New England Journal of Medicine
TREM2 variants in Alzheimer's disease
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al.
Abstract summary
Companion study to Jonsson et al. (2013) identifying the R47H variant in TREM2 as conferring a three-fold increased risk of late-onset Alzheimer's disease. Whole-exome sequencing across multiple AD cohorts confirmed TREM2 as a significant microglial genetic risk factor.
Evidence labels
human genetics
Targets
Diseases
- Alzheimer's disease
Species
human
Methods
whole-exome sequencing, case-control study
Therapeutic relevance
Co-established TREM2 as a major Alzheimer's disease drug target, catalyzing multiple antibody and small-molecule programs.
Last reviewed: June 1, 2026